WO2005023275A1 - Pharmarzeutischer wirkstoff gegen hepatitis - Google Patents
Pharmarzeutischer wirkstoff gegen hepatitis Download PDFInfo
- Publication number
- WO2005023275A1 WO2005023275A1 PCT/DE2004/001987 DE2004001987W WO2005023275A1 WO 2005023275 A1 WO2005023275 A1 WO 2005023275A1 DE 2004001987 W DE2004001987 W DE 2004001987W WO 2005023275 A1 WO2005023275 A1 WO 2005023275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- active
- enzyme
- oral secretion
- antagonistic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- a pharmaceutical active ingredient is known from DE 19961 141 A1, in which it was found that components of the spider venom from spiders of the Sicaridae family can be used for the treatment of tumor diseases. Mainly, a peptide toxin from the poison of this type of spider, a further antagonistic substance obtained from the poison and / or a combination of these components are used medically.
- This active ingredient can be used for the treatment of tumor diseases and in parallel or in support of tumor operations and residual tumor tissue can be destroyed. Genetically modified body cells (tumor cells) can be destroyed during therapy, since the active substance in question recognizes the changed surface structure of such cells and kills them without complications.
- the total poison content of this type of spider, a cocktail of various substances, so to speak, cannot be used pharmaceutically due to its lethal effect even in low doses.
- hepatitis C The situation is completely different with another variant of jaundice, hepatitis C. It is usually less serious than hepatitis B and causes chronic rather than acute symptoms. Sometimes, however, it can also lead to cirrhosis of the liver or even liver cancer. The problem here is that there is still no vaccine against hepatitis C. It is a relatively new disease because it has only been around for about 30 years. Some experts believe that 400 million people worldwide are now infected with the hepatitis C virus. Many people with HIV are also infected with hepatitis B or C. The course of hepatitis can be complicated by liver stress due to HIV medication. Then the hepatitis can flare up again temporarily.
- Komodo dragon (Varanus komodoensis). It occurs only on the island of Komodo and on a few surrounding islands in the Southeast Asian Sund archipelago.
- the lizards' scales are colored very differently.
- the color palette ranges from gray to muted green to brown. Some species have a pronounced pattern, such as horizontal stripes and dots.
- the ways of moving the monitor lizards are extremely versatile. All monitor lizards are good swimmers and divers. They put their legs back against the body and steer with their long tail. Except for full-grown Komodo dragons, all species, some of which are almost pure tree dwellers, are good climbers. Despite their sometimes massive shape, monitor lizards are good and fast runners.
- the monitor lizards are mostly carnivores, but they also have a penchant for eggs. Just like the snakes, they can expand their throats particularly heavily and thus devour very large chunks of food. They hunt all the animals that can overwhelm them. These are, for example, snakes, lizards, insects, small mammals, birds and even whole turtles. Monitor lizards don't despise carrion either. A Komodo dragon even hunts small deer and wild boar.
- the antagonistic or synergistic substance is a mixture of the phospholipases and hyaluronidases and / or toxins present in other species.
- the oral secretion and the substance having an antagonistic and / or synergistic effect can be obtained by known fractionation processes for the separation of proteins from the mouth saliva. It is preferred that the substances obtained and those that have an antagonistic or synergistic effect Substance can be obtained by gel chromatography, HPC, affinity chromatography and / or ion exchange chromatography.
- the required proportions are chosen so that the active ingredient according to the invention has no or only a slight toxic effect in the patient to be treated.
- the amounts of the active pharmaceutical ingredients must also be matched to the type of illness to be treated and the physical, possibly also psychological, circumstances of the respective patient.
- the preliminary tests required for such coordination are to be carried out by the person skilled in the art in the context of animal tests and / or ethically justifiable tests on the patient on the basis of his technical knowledge and ability.
- an active pharmaceutical ingredient in which the amount of. Oral secretions, and the antagonistic or synergistic substance for this purpose has a further amount of homeopathic substance, enzymes and antagonistic or synergistic substance, which is chosen depending on the disease to be treated.
- the oral secretion and the antagonistic or synergistic substance are used in combination with the homeopathic substance in the pharmaceutical active ingredient according to the invention.
- the active ingredient described is obtained by methods customary in chemical process engineering. This includes in particular fractionation processes; however, other methods can also be used, for example immunological methods to obtain the desired substances from the. Oral secretions to get out
- the mode of action of the oral secretions or of individual substances separated therefrom by column chromatography and characterized by the molecular weight can be carried out by testing them in corresponding healthy and diseased human cell lines.
- the substances used preferably originate from the same organism as the substances which have an antagonistic or synergistic effect and / or further active substances optionally present. In this way, the effective interaction or counterplay of these substances developed by nature can be exploited.
- the mucopolysaccharides are removed by column chromatography from the mouth.
- hepatitis C titer a dose of 1 to 2 ml i.m. administered.
- the course of the disease was monitored every 4 weeks by measuring the hepatitis C virus titer.
- the duration of treatment depends on the original titer level and can be 4 to 20 weeks before the desired titer reduction.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04786710A EP1699471A1 (de) | 2003-09-09 | 2004-09-07 | Pharmarzeutischer wirkstoff gegen hepatitis |
DE112004002231T DE112004002231D2 (de) | 2003-09-09 | 2004-09-07 | Pharmazeutischer Wirkstoff gegen Hepatitis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10341518.1 | 2003-09-09 | ||
DE10341518A DE10341518A1 (de) | 2003-09-09 | 2003-09-09 | Pharmazeutischer Wirkstoff gegen Hepatitis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023275A1 true WO2005023275A1 (de) | 2005-03-17 |
Family
ID=34223498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2004/001987 WO2005023275A1 (de) | 2003-09-09 | 2004-09-07 | Pharmarzeutischer wirkstoff gegen hepatitis |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1699471A1 (de) |
DE (2) | DE10341518A1 (de) |
WO (1) | WO2005023275A1 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1253013A (zh) * | 1999-10-25 | 2000-05-17 | 车兴泉 | 一种肝病治疗药及其制造方法 |
CN1406620A (zh) * | 2001-09-13 | 2003-04-02 | 李建生 | 一种治疗虚症的中成药及其制法 |
-
2003
- 2003-09-09 DE DE10341518A patent/DE10341518A1/de not_active Withdrawn
-
2004
- 2004-09-07 WO PCT/DE2004/001987 patent/WO2005023275A1/de active Application Filing
- 2004-09-07 DE DE112004002231T patent/DE112004002231D2/de not_active Expired - Fee Related
- 2004-09-07 EP EP04786710A patent/EP1699471A1/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1253013A (zh) * | 1999-10-25 | 2000-05-17 | 车兴泉 | 一种肝病治疗药及其制造方法 |
CN1406620A (zh) * | 2001-09-13 | 2003-04-02 | 李建生 | 一种治疗虚症的中成药及其制法 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 200041, Derwent World Patents Index; Class B04, AN 2000-466482, XP002310501 * |
DATABASE WPI Section Ch Week 200350, Derwent World Patents Index; Class B04, AN 2003-524188, XP002310502 * |
Also Published As
Publication number | Publication date |
---|---|
DE112004002231D2 (de) | 2006-07-27 |
EP1699471A1 (de) | 2006-09-13 |
DE10341518A1 (de) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001043754A2 (de) | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen | |
DE102005038768A1 (de) | Pharmazeutischer Wirkstoff gegen Borreliose | |
WO2006029605A1 (de) | Verfahren und wirkstoff zur bekämpfung von plasmodien | |
WO2005023275A1 (de) | Pharmarzeutischer wirkstoff gegen hepatitis | |
DE10163602A1 (de) | Mittel mit Nematoden und Plathelminthen zur Behandlung allergischer Erkrankungen | |
WO2005009449A1 (de) | Pharmazeutischer wirkstoff gegen warzen, herpes simplex und herpes zoster | |
WO2007060252A2 (de) | Pharmazeutischer wirkstoff zur behandlung von hepatitis, borreliose und multipler sklerose | |
WO2006032245A1 (de) | Pharmazeutischer wirkstoff gegen das hiv - syndro | |
EP2155335B1 (de) | Pharmazeutische zusammensetzung, verwendung der pharmazeutischen zusammensetzung zur behandlung eines hirntumors, herstellungsverfahren derselben sowie ein kit of parts, enthaltend die pharmazeutische zusammensetzung | |
WO2005007177A1 (de) | Pharmazeutischer wirkstoff gegen magengeschwüre | |
EP1699472A1 (de) | Pharmarzeutischer wirkstoff gegen brustkrebs | |
WO2006081808A1 (de) | Pharmazeutischer wirkstoff zur behandlung von multipler sklerose und aids | |
WO2006034691A1 (de) | Pharmazeutischer wirkstoff zur stärkung des immunsystems | |
DE10357970A1 (de) | Lösungsmittel für biogene pharmazeutische Wirkstoffe | |
EP1754486A2 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Hepatitis, Borreliose und Multipler Sklerose | |
DE10324861A1 (de) | Pharmazeutischer Wirkstoff | |
DE10330712A1 (de) | Pharmarzeutischer Wirkstoff gegen Kolonkarzinome und andere Tumorarten | |
WO2005027942A1 (de) | Pharmazeutischer wirkstoff aus schlangengift gegen melanome | |
DE102005027478A1 (de) | Pharmazeutischer Wirkstoff gegen Nierenzellkarzinome und dessen Lösungsmittel | |
WO2004108147A1 (de) | Pharmazeutischer wirkstoff | |
DE102005027665A1 (de) | Pharmazeutischer Wirkstoff zur Überwindung der Blut-Hirn-Schranke in Verbindung mit einem aus biogenen Giften gewonnenen Wirkstoff gegen Hirntumore | |
DE102004033818A1 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Multipler Sklerose | |
WO2004103384A1 (de) | Pharmazeutischer wirkstoff enthaltend ein peptidtoxin aus dem gift von schlangen der familie crotalus | |
WO2005103231A2 (de) | Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen | |
WO2005002494A2 (de) | Pharmazeutischer wirkstoff gegen prostatakarzinome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1120040022312 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004786710 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 112004002231 Country of ref document: DE Date of ref document: 20060727 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112004002231 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004786710 Country of ref document: EP |